SCHEMBL3004036

SCHEMBL3004036

COc1cccc(Nc2nc(Cl)nc3[nH]cnc23)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.54
LMNA P02545 1/20 0.54
HTT P42858 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
GRM4 Q14833 1/20 0.48
SYK P43405 1/20 0.47
SRC P12931 2/20 0.47
EGFR P00533 3/20 0.46
ERBB3 P21860 1/20 0.46
KDR P35968 2/20 0.46
PDGFRB P09619 1/20 0.46
LRRK2 Q5S007 2/20 0.45
DYRK3 O43781 1/20 0.45
MAP4K4 O95819 1/20 0.45
PDGFRA P16234 1/20 0.45
LTK P29376 1/20 0.45
GRK5 P34947 1/20 0.45
MAPK8 P45983 1/20 0.45
CDK8 P49336 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30719583 1.00 NPC1 (0.54) NPC1LMNAHTTRAB9ASMN1; SMN2
SCHEMBL3010051 0.89 SMN1; SMN2 (0.45) NPC1LMNAHTTRAB9ASMN1; SMN2
SCHEMBL24862147 0.88 BRAF (0.40) NPC1LMNAHTTRAB9ASMN1; SMN2
SCHEMBL2998386 0.86 NPC1 (0.55) NPC1LMNAHTTRAB9ASMN1; SMN2
SCHEMBL2991717 0.85 HTT (0.54) NPC1LMNAHTTRAB9ASMN1; SMN2
SCHEMBL29355778 0.85 HTT (0.54) NPC1LMNAHTTRAB9ASMN1; SMN2
SCHEMBL3006445 0.85 EGFR (0.56) NPC1LMNAHTTRAB9ASMN1; SMN2
SCHEMBL30162946 0.85 EGFR (0.56) NPC1LMNAHTTRAB9ASMN1; SMN2
SCHEMBL3000771 0.85 MAPT (0.52) NPC1RAB9ASMN1; SMN2SYKSRC
SCHEMBL3001568 0.83 BRAF (0.53) GRM4SYKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270581-A1 METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE MONSANTO TECHNOLOGY LLC (US) 2025-08-28 US disclosed
EP-4602036-A1 SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES Bayer Aktiengesellschaft (DE) 2025-08-20 EP disclosed
US-20250228243-A1 METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE MONSANTO TECHNOLOGY LLC (US) 2025-07-17 US disclosed
WO-2025122384-A1 METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE MONSANTO TECHNOLOGY LLC (US) 2025-06-12 WO disclosed
WO-2025103931-A1 SUBSTITUTED CYCLOPROPYLOXYPHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2025-05-22 WO disclosed
EP-4509511-A1 SUBSTITUTED SPIRO-ISOXAZOLINYL LACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES Bayer Aktiengesellschaft (DE) 2025-02-19 EP disclosed
WO-2024104954-A1 SUBSTITUTED CYCLOALKYLOXYPHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2024-05-23 WO disclosed
WO-2024078871-A1 1-PYRIDYL-5-PHENYLPYRAZOLYL-3-OXY- AND -3-THIOALKYL ACIDS AND DERIVATIVES AND THEIR USE FOR CONTROLLING UNDESIRED PLANT GROWTH BAYER AKTIENGESELLSCHAFT (DE) 2024-04-18 WO disclosed
WO-2024078906-A1 SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2024-04-18 WO disclosed
WO-2024020316-A2 METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE MONSANTO TECHNOLOGY LLC (US) 2024-01-25 WO disclosed
WO-2016095881-A1 SUBSTITUTED 6-ANILINO-9-HETEROCYCLYLPURINE DERIVATIVES FOR INHIBITION OF PLANT STRESS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2016-06-23 WO disclosed
EP-2173173-B1 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES UNIV PALACKEHO (CZ) 2013-07-24 EP disclosed
US-8222260-B2 Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives Univerzita Palackego V Olomouci (CZ) 2012-07-17 US disclosed
US-20100190806-A1 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2010-07-29 US disclosed
EP-2173173-A2 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES Univerzita palackeho V Olomouci (CZ) 2010-04-14 EP disclosed
WO-2009003428-A2 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2009-01-08 WO disclosed
US-7091346-B1 Purine derivatives and processes for their preparation NOVARTIS AG (CH) 2006-08-15 US disclosed
EP-0874846-B1 PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 2003-04-02 EP disclosed
EP-0874846-A1 PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1998-11-04 EP disclosed
WO-1997016452-A1 PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1997-05-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270581-A1 METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE PPOX, PTPRG, PAOX NPC1 4786/4885LMNA 4495/4885HTT 744/4885
US-20250228243-A1 METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE UNG, PNPO, PPOX NPC1 4793/4885LMNA 4459/4885HTT 1087/4885
US-20100190806-A1 SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES DPYD, XDH, APRT NPC1 4004/4885LMNA 4685/4885HTT 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.